Top 3 Health Care Stocks That Are Set To Fly This Quarter
Top 3 Health Care Stocks That Are Set To Fly This Quarter
前三家医疗保健股票在本季度有望上涨
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
医疗保健板块中最超卖的股票为买入被低估的公司提供了机会。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI指标是一种动量指标,它比较了股票在价格上涨时的强度与在价格下跌时的强度。与股票的价格走势进行比较,可以给交易者更好的了解股票短期内表现的良好程度。当RSI低于30时,资产通常被认为是超卖的,根据Benzinga Pro的数据。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是本行业板块最近的主要超卖股票列表,RSI接近或低于30。
Haemonetics Corporation (NYSE:HAE)
美国血液技术公司(NYSE:HAE)
- On Aug. 8, Haemonetics posted better-than-expected quarterly earnings. The company's stock fell around 19% over the past month and has a 52-week low of $70.74.
- RSI Value: 25.47
- HAE Price Action: Shares of Haemonetics gained 1.1% to close at $73.99 on Thursday.
- Benzinga Pro's real-time newsfeed alerted to latest HAE news.
- 8月8日,美国血液技术公司发布了好于预期的季度财报,该公司的股票在过去一个月下跌了约19%,52周最低股价为70.74美元。
- RSI数值:25.47
- 美国血液技术公司股票价格变化:周四,美国血液技术公司的股票上涨了1.1%,收于73.99美元。
- Benzinga Pro的实时新闻提醒了最新的美国血液技术公司新闻。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240816/0-605260f8ff156e1aeb536bd699e43383-0-0b844f930b85737c4f615f6864330c6b.png/big)
Immunitybio Inc (NASDAQ:IBRX)
Immunitybio Inc(NASDAQ:IBRX)
- On Aug. 6, ImmunityBio announced study of ANKTIVA in combination with the AdHER2DC cancer vaccine as a potential therapy to control endometrial cancer. The company's stock fell around 38% over the past month. It has a 52-week low of $1.25.
- RSI Value: 29.87
- IBRX Price Action: Shares of Immunitybio rose 2.6% to close at $3.98 on Thursday.
- Benzinga Pro's charting tool helped identify the trend in IBRX stock.
- 8月6日,ImmunityBio宣布了ANKTIVA与AdHER2DC癌症疫苗联合治疗子宫内膜癌的研究作为一种潜在的治疗方案。 该公司的股票在过去一个月下跌了约38%,52周最低股价为1.25美元。
- RSI数值:29.87
- Immunitybio股票价格变化:周四,Immunitybio的股票上涨了2.6%,收于3.98美元。
- Benzinga Pro的图表工具帮助识别IBRX股票的趋势。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240816/0-605260f8ff156e1aeb536bd699e43383-1-380c0c71358f5d6caa349dec20f862b2.png/big)
Progyny Inc (NASDAQ:PGNY)
Progyny Inc(NASDAQ:PGNY)
- On Aug. 6, Progyny reported worse-than-expected second-quarter revenue results. "The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healthy and within the range of our long-established patterns," said Pete Anevski, Chief Executive Officer of Progyny. The company's shares fell around 31% over the past month and has a 52-week low of $19.60.
- RSI Value: 29.06
- PGNY Price Action: Shares of Progyny rose 1.7% to close at $20.85 on Thursday.
- Benzinga Pro's signals feature notified of a potential breakout in PGNY shares.
- 8月6日,Progyny公布了不如预期的第二季度营业收入结果。 “第二季度利用率率与我们的预期一致,表明治疗需求仍保持健康并符合我们长期建立的模式。” Pete Anevski,Progyny的首席执行官说。该公司的股票在过去一个月下跌了约31%,52周最低股价为19.60美元。
- RSI数值:29.06
- Progyny股票价格变化:周四,Progyny的股票上涨了1.7%,收于20.85美元。
- Benzinga Pro的信号功能提示了PGNY股票的潜在突破。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240816/0-605260f8ff156e1aeb536bd699e43383-2-524aae51789f2ef203b380dc769be943.png/big)
- Jim Cramer Recommends Buying Clorox: 'CEO Has Done Remarkable Job'
- 吉姆·克莱默推荐购买高乐氏:'CEO表现出色'